title: Safety and efficacy of Adalimumab in the treatment of moderate to severe palmo-plantar psoriasis: an open label study.
abstract: BACKGROUND
  Psoriasis of the hands and feet is highly debilitating and difficult to treat. Lesions are very painfull, disabilitating and impair quality of life of patients. Most treatment options have limited efficacy, short duration of response and several adverse events.
  
  
  OBJECTIVE
  To investigate the safety and efficacy of Adalimumab in the management of palmo-plantar psoriasis.
  
  
  METHODS
  Adults patients with moderate to severe palmoplantar psoriasis were enrollend in this trial. They received a 6 courses of Adalimumab 40 mg 1 vial every 2 weeks. The study consisted of treatment period of 12 weeks (Weeks 1-12). Safety and efficacy were assessed at weeks 0.6 and 12. PGA (Physician's Global Assesment) and DLQI were used to measure the efficacy. Primary end point of the study was to evaluate patients who achieved a reduction in PGA at week 12. The secondary end point was to evaluate patients who achieved a 50% reduction in PGA at week 12. The tertiary end point evaluated patients who achieved a PGA rating of clear or almost clear.
  
  
  RESULTS
  Of 11 patients enrolled 6 showed overall improvement of at least one point of PGA at week 12; 4 of them obtained a PGA of 0 while 5 patient of 11 a ≥ 50% improvement from the beginning of the study. 8 patients showed an increase in quality of life score while receiving the drug at week 12. No serious adverse events were reported during the study.
  
  
  CONCLUSIONS
  Continuous treatment with Adalimumab for 12 weeks was safe and efficacious in this open-label clinical trial of patients with palmoplantar psoriasis.
authors.affiliation: Department of Dermatology and Venereology, Policlinico Umberto I, Rome, Italy. antoniorichetta@hotmail.it
authors.forename: A G
authors.initials: AG
authors.lastname: Richetta
authors.forename: C
authors.initials: C
authors.lastname: Mattozzi
authors.forename: S
authors.initials: S
authors.lastname: Giancristoforo
authors.forename: S
authors.initials: S
authors.lastname: D'Epiro
authors.forename: C
authors.initials: C
authors.lastname: Cantisani
authors.forename: L
authors.initials: L
authors.lastname: Macaluso
authors.forename: M
authors.initials: M
authors.lastname: Salvi
authors.forename: S
authors.initials: S
authors.lastname: Calvieri
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012720:Severity of Illness Index
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab